Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-18. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
=== Charitable activities === Hooters has actively supported charities through its Hooters Community Endowment Fund, also known as HOO.C.E.F., a play on UNICEF. It has provided money and/or volunteers to charities such as Habitat for Humanity, The V Foundation for Cancer Research, Operation Homefront, Make-A-Wish Foundation, Special Olympics, Muscular Dystrophy Association and Stop Hunger Now. In addition, after the 2007 death of Kelly Jo Dowd, a former Hooters Girl, Hooters calendar cover girl and later restaurant general manager, Hooters began a campaign in support of breast cancer research, with awareness of the issue being spread through the Kelly Jo Dowd Fund. By 2010 the chain raised over $2 million for the cause. One dollar of each calendar sold goes for breast cancer research. In 2009, Hooters partnered with Operation Homefront to establish The Valentine Fund in honor of fallen soldier SOCS Thomas J. Valentine. The fund supports the families of US Special Forces service members and other military families. Thomas J. Valentine, a Navy SEAL Senior Chief Petty Officer, was killed during a training exercise February 13, 2008. He left behind his wife, Christina, and two young children. Hooters established a fund in Valentine's name through Operation Homefront.
=== Marketing === It may be used in generic labels and store brands, Benylin DM, Mucinex DM, Camydex-20 tablets, Komix DT, NyQuil, Dimetapp, Vicks, Coricidin, Delsym, TheraFlu, Charcoal D, Medicon Cinfatós and others.
== Interactions == Sauvagine has been shown to interact with corticotropin releasing factor receptors 1 and 2, and (as with other CRF-related peptides) is also bound by the corticotropin-releasing factor binding protein.
Loss of sovereignty: membership often comes with a loss of state sovereignty as treaties are signed that require co-operation on the part of all member states. Insufficient benefits: often membership does not bring about substantial enough benefit to warrant membership in the organization. Attractive external options: bilateral co-operation with external actors or competing IGOs may provide more attractive (external) policy options for member states. Thus, powerful external actors may undermine existing IGOs.
Sources: en.wikipedia.org
The most recognizable contributions of the Stalinist period may be the so-called Seven Sisters, seven large skyscrapers distributed around the city at approximately equal distances from the Kremlin. A defining feature of Moscow's skyline, their imposing form was allegedly inspired by the Manhattan Municipal Building in New York City; their style—with intricate exteriors and a large central spire—has been described as Stalinist Gothic architecture. All seven towers can be seen from most elevated locations in the city. These towers are among the tallest constructions in central Moscow apart from the Ostankino Tower; when this tower was completed in 1967, it was the highest freestanding land structure in the world. It remains the world's seventy-second tallest, ranked among buildings such as the Burj Khalifa in Dubai, Taipei 101 in Taiwan, and the CN Tower in Toronto. The Soviet goal of providing housing for every family, along with the rapid growth of Moscow's population, led to the construction of large, monotonous housing blocks. Most of these were built after Stalin's era, and their styles are often named after the contemporary leader (e.g., Brezhnev and Khrushchev). These blocks are usually badly maintained. Although the city retains some five-story apartment buildings constructed before the mid-1960s, more recent apartment buildings are usually at least nine stories tall and have elevators. Moscow is estimated to have more than twice as many elevators as New York City and four times as many as Chicago.
Only the chordates (including vertebrates) and the hemichordates have a central "heart", which is a vesicle formed from the thickening of the aorta and contracts to pump blood. This suggests a presence of it in the last common ancestor of these groups (may have been lost in the echinoderms).
is the cross-sectional area, which can often be reasonably approximated as a rectangle with the characteristic width and depth. This absorbs velocity, width, and depth. We define stream power per unit channel length, so that term goes to 1, and the derivation is complete.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.